Navigation Links
Endu Receives Gold Medal for Outstanding Chinese Patented Invention Award
Date:3/3/2008

NANJING, CHINA, March 4 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, announced today that the company is a gold medal winner of the 10th Outstanding Chinese Patented Invention Award bestowed by the State Intellectual Property Office of the People's Republic of China (SIPO).

The award, established by SIPO in 1989, is the exclusive government patent award held every two years to encourage technology innovation and to boost intellectual property protection, and has been approved by the World Intellectual Property Organization (WIPO).

SIPO received 318 applicants for the 10th Outstanding Chinese Patented Invention Award from all over the country recommended by the ministries, local IP administrations, nation-level enterprises, the Chinese Academy of Sciences and the members of Chinese Academy of Engineering. Fifteen outstanding Chinese patent invention gold medal winners were selected after several rounds of strict examination.

The award is for the methodology pioneered by Simcere to produce Endu, a modified version of endostatin, which has brought tremendous social benefit to thousands of patients across China. Endu has been engineered to contain an additional nine-amino acid sequence to enhance protein purification, solubility and stability and has been shown to improve the function of endostatin, which is a genetically engineered protein that interferes with the growth of blood vessels to a tumor, thereby starving and preventing the growth of tumor cells.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR; Simcere) is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in the rapidly growing China market. In recent years, Simcere has focused its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic stoke management medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. Simcere currently manufactures and sells more than 50 pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Highlands Acquisition Corp. Receives Non-Compliance Letter From Amex
2. Vapotherm CEO Receives Top Business Leadership Award From World Trade Center Institute
3. Fujifilm Receives FDA Approval for Unity SpeedSuite(TM)
4. Bart De Strooper receives prestigious $200,000 Alzheimer Prize
5. The Female Health Company Receives USAID DELIVER PROJECT Order for 6.1 Million Units
6. Sirion Therapeutics Receives NDA Acceptance and Priority Review From the FDA for Durezol(TM) in the Treatment of Postoperative Ocular Inflammation
7. Boca Pharmacal Receives FDA Approval for Carbinoxamine Oral Solution
8. IDC receives patent on dual energy imaging technology
9. Kryptiq Customer Receives HIMSS Nicholas E. Davies Award of Excellence
10. Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
11. Healthy Start of Southwest Florida Receives Grant From March of Dimes to Assess Needs of Pregnant Women and Babies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... Bill Howe Plumbing, Heating ... the American Heart Association; “Howe” Healthy is Your Heart Drawing Contest The ... active. Each year, Bill Howe Plumbing, Heating & Air receives over 600 entries. The ...
(Date:1/19/2017)... Marriottsville, MD (PRWEB) , ... January 19, 2017 , ... ... launched six new clients into the US market. , Over the past 20 years ... the past 4 weeks SFI has launched six new clients into the US market. ...
(Date:1/19/2017)... Georgia (PRWEB) , ... January 19, 2017 , ... ... Surgeons hosts the Atlanta Breast Surgery Symposium, a conference where hundreds of surgeons ... advancements in breast surgery. Covering topics from cosmetic breast augmentation to ...
(Date:1/18/2017)... ... 2017 , ... A recent video posting of a new fidget product gathered ... fidgeting to relieve stress and anxiety. No one was more surprised than Think ... just completed a successful Kickstarter campaign raising $67,000 on the popular crowdfunding platform. ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... manage it from the number one doctor-recommended OTC antiperspirant, Certain Dri. , Excessive ... go untreated. , Certain Dri created this infographic to explain the seven types ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... CLEVELAND , Jan. 19, 2017 ViewRay, ... (DFG), a federal institution supporting research in ... installation and patient treatments at the University Clinic Heidelberg ... The MRIdian Linac program will be headed ... who also heads radiation oncology at the German Cancer ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017   Science ... is excited to announce that the first five ... Biology  (RP:CB) have been published in eLife today. ... project represents the first practical evaluation of reproducibility ... in reproducible studies. Unlike other assessments of reproducibility, ...
(Date:1/19/2017)... -- New Review of Safinamide - ... and Motor Complications in Mid- to Late-stage Parkinson,s ... ... C Warren Olanow , ... 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late Published recently ...
Breaking Medicine Technology: